Embosphere® PROstate Post Market Study



Status:Recruiting
Conditions:Other Indications, Hematology, Benign Prostate Hyperplasia, Urology
Therapuetic Areas:Hematology, Nephrology / Urology, Other
Healthy:No
Age Range:18 - Any
Updated:3/9/2019
Start Date:August 16, 2018
End Date:September 1, 2023
Contact:Casey Holland
Email:casey.holland@merit.com
Phone:(781) 681-7983

Use our guide to learn which trials are right for you!

A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres

Prostatic artery embolization with Embosphere Microspheres is a relatively new procedure. The
goal of this post market study is to evaluate long-term safety and effectiveness in a 'real
world' setting.

This is a prospective, open label post market study to evaluate the long-term safety and
effectiveness of prostatic artery embolization (PAE) using Embosphere Microspheres. Up to
1,000 patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia
(BPH) will be enrolled in this single arm post market study. All patients at sites who meet
eligibility criteria will be offered participation. Long term effectiveness of PAE on LUTS
will be evaluated by International Prostate Symptom Score (IPSS) at baseline, 3 months, 12
months, 24 months and 36 months. Safety will be assessed by evaluating treatment related
adverse events at the same time points, plus at 4 weeks following embolization. Erectile
function will be assessed at baseline and 12 months by Sexual Health Inventory for Men (SHIM)
score. Additional treatments for refractory or recurrent LUTS due to BPH post prostatic
artery embolization will also be recorded.

Eligibility Criteria Inclusion Criteria

- Patient has signed informed consent

- Patient age is 18 years or older at time of informed consent

- Patient will undergo PAE with Embosphere Microspheres for the treatment of symptomatic
BPH with LUTS

Exclusion Criteria

- Patient is unable or unwilling to provide follow-up information

- Patient is undergoing PAE for reasons that do not include symptomatic BPH with LUTS

- Any other reason the investigator deems cause for exclusion

A treatment-related adverse event is defined in this post market study as any event that
began on or after the date of the PAE procedure and is considered related to the study
procedure by the investigator. All related events must be reported in the case report form
and followed until resolution.Any treatment-related serious adverse events (SAE) that occurs
on or after the date of the PAE or worsened in severity or frequency after the PAE must be
reported to the Sponsor immediately (not to exceed 24 hours within site notification of the
event) in the case report form or via email. It is the responsibility of Investigators to
inform their Review Board/ Ethics Committee (IRB/EC) of complications or serious injury as
required by their Institutional Review Board/ Ethics Committee (IRB/EC) procedure and/or
federal law.

After the study has been fully explained, written informed consent will be obtained from
either the patient or his guardian or legal representative prior to any study procedures. The
method of obtaining and documenting the informed consent and the contents of the consent will
comply with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and
all applicable regulatory requirement(s).

Inclusion Criteria:

- Patient has signed informed consent

- Patient age is 18 years or older at time of informed consent

- Patient will undergo prostatic artery embolization with Embosphere Microspheres for
the treatment of symptomatic benign prostatic hyperplasia with lower urinary tract
symptoms

Exclusion Criteria:

- Patient is unable or unwilling to provide follow-up information

- Patient is undergoing prostatic artery embolization for reasons that do not include
symptomatic benign prostatic hyperplasia with lower urinary tract symptoms

- Any other reason the investigator deems cause for exclusion
We found this trial at
10
sites
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael Rush
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
Principal Investigator: Justin McWilliams, MD
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1601 Northwest 12th Avenue
Miami, Florida 33136
(305) 243-6545
Principal Investigator: Shivank Bhatia
University of Miami Miller School of Medicine The University of Miami Leonard M. Miller School...
?
mi
from
Miami, FL
Click here to add this to my saved trials
Long Beach, California 90822
Principal Investigator: Edward Uchio, MD
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Justin McWilliams, MD
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
722 W 168th St
New York, New York 10032
(212) 305-2500
Principal Investigator: David Mobley, MD
Columbia Presbyterian Med Ctr On January 1, 1998, The New York Hospital publicly announced its...
?
mi
from
New York, NY
Click here to add this to my saved trials
Orange, California
Principal Investigator: Edward Uchio, MD
?
mi
from
Orange, CA
Click here to add this to my saved trials
Paris, 75015
Principal Investigator: Marc Sapoval, MD
?
mi
from
Paris,
Click here to add this to my saved trials
3635 Vista at Grand Ave.
Saint Louis, Missouri 63110
Principal Investigator: Keith Pereira, MD
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Spokane, Washington 99204
Principal Investigator: Jayson Brower, MD
?
mi
from
Spokane, WA
Click here to add this to my saved trials